SRPTNasdaqPharmaceutical PreparationsFiscal year ends December 31

Sarepta Therapeutics, Inc.

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026

$17.73+0.63 (+3.68%)

Close on Oct 19, 2026

Market cap: $1.87B
P/E (TTM): –
Dividend yield: –

Sarepta Therapeutics, Inc. balance sheet

Annual Quarterly

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31	FY 2019 2019-12-31	FY 2018 2018-12-31	FY 2017 2017-12-31	FY 2016 2016-12-31	FY 2015 2015-12-31	FY 2014 2014-12-31	FY 2013 2013-12-31	FY 2012 2012-12-31	FY 2011 2011-12-31	FY 2010 2010-12-31	FY 2009 2009-12-31	FY 2008 2008-12-31
Cash & Equivalents	801	1,119	428	967	2,116	1,503	835	371	600	122	80	74	257	188	40	34	48	11
Short-Term Investments	138	252	1,248	1,023	0	436	290	803	479	195	112	137	0	–	–	–	–	–
Cash & Short-Term Investments	940	1,370	1,692	2,008	2,126	1,948	1,134	1,175	1,090	329	204	211	265	188	40	34	48	11
Receivables	398	602	400	215	153	101	91	49	29	5.23	3.98	2.42	3.53	4.71	3.63	3.22	–	–
Inventory	915	750	323	204	186	232	171	125	84	13	–	–	–	–	–	–	–	–
Prepaid Expenses & Other	–	–	–	–	–	–	–	–	–	1.16	3.11	2.80	2.42	–	–	–	–	–
Other Current Assets	172	90	78	150	149	213	82	78	37	27	17	35	3.06	1.53	1.65	1.03	–	–
Total Current Assets	2,538	3,073	2,579	2,558	2,604	2,485	1,469	1,426	1,229	373	225	248	271	194	45	38	–	–
Property, Plant & Equipment	345	340	227	180	191	190	130	97	43	38	37	39	15	3.40	4.27	2.07	–	–
Gross Property, Plant & Equipment	626	574	418	329	304	266	181	125	61	68	62	58	32	20	20	–	–	–
Accumulated Depreciation	-280	-234	-191	-149	-113	-76	-51	-28	-18	-30	-25	-20	-17	-17	-16	-15	–	–
Construction in Progress	–	–	–	–	–	–	–	–	–	–	–	–	11	–	–	–	–	–
Long-Term Investments	1.05	133	0	–	–	–	–	–	9.98	–	–	–	–	–	–	–	–	–
Operating Lease Right-of-Use Assets	125	148	130	65	46	92	38	43	–	–	–	–	–	–	–	–	–	–
Intangible Assets	29	27	30	7.58	14	14	12	12	14	8.08	6.64	5.89	5.04	4.91	4.76	3.98	–	–
Other Long-Term Assets	156	80	137	163	293	204	174	107	22	3.97	4.47	2.06	0.03	2.78	0.16	0.12	–	–
Total Assets	3,350	3,963	3,265	3,128	3,148	2,985	1,823	1,642	1,308	424	274	295	292	205	54	46	–	–
Accounts Payable	281	214	165	96	77	111	68	34	8.47	30	20	12	8.08	7.53	9.40	1.31	–	–
Accrued Expenses	360	374	315	419	272	194	186	134	69	31	29	17	15	–	–	–	–	–
Current Portion of Long-Term Debt	–	0	105	0	–	–	–	–	–	–	–	0.10	0.09	0.09	0.09	0.08	–	–
Current Debt	–	0	105	0	–	–	–	–	–	–	–	0.10	0.09	0.09	0.09	0.08	–	–
Current Portion of Leases	11	13	18	15	15	21	7.85	–	–	–	–	–	–	–	–	–	–	–
Current Income Taxes Payable	–	–	–	–	–	–	–	0.30	0.94	–	–	–	–	–	–	–	–	–
Deferred Revenue (Current)	443	130	50	89	89	89	3.30	3.30	3.32	3.30	3.30	3.32	3.30	3.30	3.30	3.30	–	–
Other Current Liabilities	11	13	18	15	15	22	7.84	5.77	1.39	1.31	1.28	1.19	0.89	0.03	0.13	0.04	–	–
Total Current Liabilities	1,095	732	654	620	453	416	265	174	88	75	62	37	36	79	21	46	–	–
Long-Term Debt	–	–	–	–	–	–	–	–	–	–	–	2.26	1.58	1.67	1.76	1.84	–	–
Long-Term Leases	199	192	141	58	42	80	48	–	–	–	–	–	–	–	–	–	–	–
Operating Lease Liabilities	211	206	159	73	57	101	56	60	–	–	–	–	–	–	–	–	–	–
Other Long-Term Liabilities	1.53	1.75	3.00	0.04	11	20	5.05	16	5.54	5.95	6.17	6.78	6.84	0.76	–	–	–	–
Total Liabilities	2,209	2,435	2,405	2,743	2,220	2,223	1,005	610	519	87	83	47	44	81	23	49	–	–
Total Debt	–	0	105	0	–	–	–	–	–	–	–	2.36	1.67	1.76	1.84	1.92	–	–
Preferred Stock	0	0	0	0	0	–	–	–	–	–	–	–	0	0	0	–	–	–
Common Stock	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.01	0.00	0.00	0.00	0.00	0.01	–	–
Additional Paid-In Capital	6,043	5,739	5,305	4,297	4,135	3,610	3,112	2,611	2,007	1,503	1,090	927	790	555	341	305	–	–
Retained Earnings	-4,877	-4,211	-4,446	-3,910	-3,207	-2,848	-2,294	-1,579	-1,217	-1,166	-899	-679	-543	–	–	–	–	–
Treasury Stock	-25	0	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–	–
Comprehensive Income & Other	0.27	-0.22	0.92	-1.66	-0.02	0.00	0.05	-0.10	-0.38	-0.12	-0.11	-0.10	0	–	–	–	–	–
Shareholders' Equity	1,141	1,528	859	385	928	762	818	1,032	789	337	190	248	247	124	31	-2.82	–	–
Total Equity	1,141	1,528	859	385	928	762	818	1,032	789	337	190	248	247	124	31	-2.82	24	16
Total Liabilities & Equity	3,350	3,963	3,265	3,128	3,148	2,985	1,823	1,642	1,308	424	274	295	292	205	54	46	–	–
Shares Outstanding(shares)	105	97	94	88	87	79	75	71	65	55	46	41	38	32	23	19	–	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 110.0%
Operating margin: -7.3%
Net margin: -6.9%
Return on equity, FY2025: -53.5%

Financial strength

Current ratio: 4.42
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 113.6%

Valuation

P/E ratio: –
Price to sales: 0.95
Price to book: 1.22
Dividend yield: –